Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
4.110
-0.090 (-2.14%)
At close: Mar 28, 2025, 4:00 PM
4.214
+0.104 (2.54%)
After-hours: Mar 28, 2025, 5:14 PM EDT
Olema Pharmaceuticals Stock Forecast
OLMA's stock price has decreased by -63.3% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Olema Pharmaceuticals stock have an average target of 26.75, with a low estimate of 24 and a high estimate of 30. The average target predicts an increase of 550.85% from the current stock price of 4.11.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Olema Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $30 → $28 | Buy | Maintains | $30 → $28 | +581.27% | Mar 28, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $30 → $25 | Buy | Reiterates | $30 → $25 | +508.27% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +629.93% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +629.93% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +629.93% | Mar 5, 2025 |
Financial Forecast
Revenue This Year
n/a
from 340.22M
Revenue Next Year
n/a
EPS This Year
-2.51
from -2.20
EPS Next Year
-2.87
from -2.51
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 23.6M | 52.5M | ||
| Avg | n/a | 5.7M | 38.2M | ||
| Low | n/a | n/a | 24.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 815.0% | ||
| Avg | - | - | 565.7% | ||
| Low | - | - | 325.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.22 | -2.06 | -1.98 | ||
| Avg | -2.51 | -2.87 | -2.73 | ||
| Low | -2.97 | -3.78 | -3.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.